See the DrugPatentWatch profile for keytruda

Keytruda, a medication approved by the FDA for the treatment of several types of cancer, may not be suitable for everyone. While each patient's situation is unique, certain groups of people should generally avoid Keytruda.

Firstly, individuals with a known hypersensitivity to pembrolizumab, the active ingredient in Keytruda, or any of its excipients should not use this medication [1]. Additionally, Keytruda is not recommended for patients with untreated autoimmune disorders, as it can exacerbate these conditions [1].

Pregnant women should avoid Keytruda, as it can cause harm to the fetus [1]. Women of childbearing age should use effective contraception during treatment and for at least 4 months after the last dose [1]. Men with female partners of reproductive potential should also use contraception during treatment and for at least 4 months after the last dose [1].

Patients with a history of severe immune-mediated adverse reactions to other PD-1/PD-L1 inhibitors should avoid Keytruda [1]. Furthermore, patients with a history of solid organ transplant, or those who are currently on immunosuppressive therapy, should use Keytruda with caution, as it may affect the effectiveness of the transplant or the immunosuppressive therapy [1].

Lastly, patients with active hepatitis B or C, or HIV, should use Keytruda with caution, as it can exacerbate these conditions [1].

In conclusion, while Keytruda can be an effective treatment for certain types of cancer, it is not suitable for everyone. Patients should discuss their medical history and current health status with their healthcare provider to determine if Keytruda is a safe and appropriate treatment option for them.

Sources:
[1] DrugPatentWatch.com. (n.d.). Keytruda (pembrolizumab) - DrugPatentWatch. Retrieved from <https://www.drugpatentwatch.com/drugs/keytruda>